Hydralazine Dosing
For intravenous hydralazine in hypertensive emergencies, initiate with 10 mg via slow IV infusion (maximum initial dose 20 mg) and repeat every 4-6 hours as needed, though this agent is not a desirable first-line choice due to unpredictable response and prolonged duration of action. 1, 2, 3, 4
Intravenous Dosing
Hypertensive Emergencies
- Initial dose: 10 mg via slow IV infusion (maximum initial dose 20 mg)
- Repeat dosing: Every 4-6 hours as needed
- Onset: Blood pressure begins to decrease within 10-30 minutes
- Duration: Effect lasts 2-4 hours 1, 2, 3
Critical caveat: The 2017 ACC/AHA guidelines explicitly state that the unpredictability of response and prolonged duration of action do not make hydralazine a desirable first-line agent for acute treatment in most patients. 1, 2, 3 Consider nicardipine or labetalol as preferred alternatives for hypertensive emergencies.
FDA-Approved IV Dosing
The FDA label specifies 20-40 mg repeated as necessary, with lower doses required for patients with marked renal damage. 5 Blood pressure should be checked frequently, with maximal decrease occurring in 10-80 minutes. The product should be used immediately after opening and not added to infusion solutions. 5
Oral Dosing
Chronic Heart Failure (with Isosorbide Dinitrate)
For heart failure with reduced ejection fraction, particularly in African-American patients or those intolerant to ACE inhibitors/ARBs:
Fixed-Dose Combination
- Initial: 37.5 mg hydralazine/20 mg isosorbide dinitrate three times daily
- Target: 75 mg hydralazine/40 mg isosorbide dinitrate three times daily
- Mean dose achieved in trials: ~175 mg hydralazine/90 mg isosorbide dinitrate daily 6
Individual Components
- Hydralazine initial: 25-50 mg three or four times daily
- Hydralazine maximum: 300 mg daily in divided doses
- Isosorbide dinitrate initial: 20-30 mg three or four times daily
- Isosorbide dinitrate maximum: 120 mg daily in divided doses 6
Chronic Hypertension
Research suggests oral doses of 75-300 mg daily divided into multiple doses, with individualization based on acetylator status and renal function. 7, 8 Studies show 50 mg doses often produce minimal hemodynamic effects, while 100 mg doses produce substantial improvements in cardiac index and systemic vascular resistance. 8
Special Populations
Elderly and Frail Patients
No specific dose adjustment is required for elderly patients according to ACC/AHA guidelines. 1, 2, 3 However, research in elderly heart failure patients (ages 71-91) used hydralazine 100-400 mg per day with careful monitoring. 9 Start at lower end of dosing range and titrate cautiously.
Renal Impairment
Patients with marked renal damage require lower doses. 5 The duration of action is significantly longer in patients with creatinine clearance <35 mL/min (14.3 ± 1.4 hours) compared to those with adequate renal function (7.9 ± 0.5 hours), necessitating longer dosing intervals. 8
Acetylator Status
The dose producing 50% of maximum antihypertensive response (D50) is 0.87 mg/kg for slow acetylators versus 1.68 mg/kg for fast acetylators, suggesting slow acetylators may require lower doses. 7
Clinical Context and Recommendations
Heart Failure Guidelines
The 2013 ACC/AHA heart failure guidelines provide Class I recommendation for hydralazine-isosorbide dinitrate combination in African-American patients with HFrEF already on ACE inhibitors and beta-blockers (Level of Evidence: A). 6 This is based on a 7% relative risk reduction in mortality and 33% reduction in hospitalizations. 6
Class IIa recommendation exists for use as alternative therapy in patients who cannot tolerate ACE inhibitors or ARBs. 10, 6
Important limitation: A 2016 real-world registry study found that adherence to hydralazine-isosorbide dinitrate was low post-discharge, and there were no differences in 3-year mortality or readmission outcomes between treated and untreated patients, contrasting with clinical trial results. 11 This suggests effectiveness in clinical practice may be limited by adherence issues.
Hypertensive Emergency Considerations
Recent evidence (2025) demonstrates that 69% of IV hydralazine use in hospitalized patients lacked appropriate indications, with frequent use for asymptomatic blood pressure elevations. 12 A 2011 study found only 2% of patients receiving IV hydralazine had evidence of urgent hypertensive conditions, with 18% experiencing adverse events, most commonly hypotension. 13
Key practice point: Reserve IV hydralazine for true hypertensive emergencies with end-organ damage, not asymptomatic blood pressure elevations. Prefer titratable agents like nicardipine or clevidipine for most hypertensive emergencies.
Dosing Individualization
Hemodynamic response to hydralazine correlates with initial systemic vascular resistance (r=0.53) and left ventricular preload status. 14 Patients with higher baseline vascular resistance and elevated pulmonary wedge pressure show greater response. This suggests starting with lower doses in patients with lower baseline resistance or less severe hemodynamic compromise.